Literature DB >> 15463734

Protective immunity in lyme borreliosis.

E Fikrig1, F S Kantor, S W Barthold, R A Flavell.   

Abstract

Lyme disease, caused by the spirochete Borrelia burgdorferi, is the most common vector-borne illness in the USA. Although early infection can be treated with antibiotics, the initial diagnosis is difficult and late disease may be recalcitrant to therapy. A vaccine against Lyme disease is therefore needed, and murine models of Lyme borreliosis have facilitated its development. In this review, Erol Fikrig, Fred Kantor, Stephen Barthold and Richard Flavell focus on the use of Borrelia surface antigens as vaccine candidates for Lyme disease.

Entities:  

Year:  1993        PMID: 15463734     DOI: 10.1016/0169-4758(93)90176-g

Source DB:  PubMed          Journal:  Parasitol Today        ISSN: 0169-4758


  4 in total

1.  Protection of C3H/HeN mice from challenge with Borrelia burgdorferi through active immunization with OspA, OspB, or OspC, but not with OspD or the 83-kilodalton antigen.

Authors:  W S Probert; R B LeFebvre
Journal:  Infect Immun       Date:  1994-05       Impact factor: 3.441

2.  Identification and characterization of a surface-exposed, 66-kilodalton protein from Borrelia burgdorferi.

Authors:  W S Probert; K M Allsup; R B LeFebvre
Journal:  Infect Immun       Date:  1995-05       Impact factor: 3.441

3.  Evaluation of the Importance of VlsE Antigenic Variation for the Enzootic Cycle of Borrelia burgdorferi.

Authors:  Artem S Rogovskyy; Timothy Casselli; Yvonne Tourand; Cami R Jones; Jeb P Owen; Kathleen L Mason; Glen A Scoles; Troy Bankhead
Journal:  PLoS One       Date:  2015-04-20       Impact factor: 3.240

4.  Experimental infections of the reservoir species Peromyscus leucopus with diverse strains of Borrelia burgdorferi, a Lyme disease agent.

Authors:  Elisabeth Baum; Fong Hue; Alan G Barbour
Journal:  mBio       Date:  2012-12-04       Impact factor: 7.867

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.